iBET is part of TRANSVAC, an EU collaborative infrastructure that combines the expertise – scientific, technical, regulatory, and financial – of multiple organizations to accelerate the development of safe, effective, and affordable vaccines.
TRANSVAC offers a wide range of high-quality technical services to support vaccine development, organised in four platforms: “Technology”, “Immunocorrelates and System Biology”, “Animal Models” and “Clinical Trial Support”. The TRANSVAC2 TNA Call to apply for these services is now open and will last until August 5th.
The services provided by TRANSVAC are not restricted to any disease in particular and the majority can be accessed free-of-charge. iBET is involved in the services related with mammalian and insect cell expression platform screening, small-scale production and purification of candidate vaccines, GMP-directed evaluation of vaccine candidate production processes, production scale-up for vaccine candidates, definition of specifications for pilot-scale production and product stability testing and delivery for GLP toxicology studies.
For more information about the services offered by TRANSVAC please visit www.transvac.org